In Silico Screening and Off-Target Counter-Screening of FDA-Approved Zinc-Chelating Therapeutics Against New Delhi Metallo-Beta-Lactamase-1 (NDM-1): Repositioning Sulbactam as a Competitive Bimetallic Inhibitor

Phase 1 preclinical in silico manuscript (AETHEL-BIO campaign AMR-NDM1). Twelve FDA-approved/clinical zinc-chelating drugs docked against NDM-1 (PDB 4EYL, calibrated on 4EYL/4EXS redocking, gate F0-1 PASS) with human MMP-9 counter-screen (PDB 1GKC), Lipinski/hERG triage and CLSI M100 wet-lab protocol. Sulbactam prioritized as the single NDM-1-selective chelating candidate (reversible non-covalent competitive blocker). Reproducibility repository: https://github.com/powermioyeah-debug/aethel-amr-ndm1. In silico hypotheses only; no efficacy claims.